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Abstract
Objective. The aim of this study was to assess the risk of active tuberculosis (TB) in patients with
immune-mediated inflammatory diseases treated with biologics and tofacitinib in randomized controlled
trials (RCTs) and long-term extension (LTE) studies.
Methods. A systematic review of the English-language literature by was performed by searching the
Medline, Embase, Cochrane and Web of Knowledge databases. The search strategy focused on syno-
nyms of diseases, biologics and tofacitinib. Data from RCTs were combined to assess the rate of TB using
a random effects model. The incidence rate (IR) of TB and its association with disease, location and
treatment were assessed in LTE studies.
Results. The search captured 11 130 articles and abstracts. One-hundred RCTs (75 000 patients) and 63
LTE studies (80 774.45 patient-years) met the inclusion criteria. There were 31 TB cases with TNF inhibi-
tors, 1 with abatacept and none with rituximab, tocilizumab, ustekinumab or tofacitinib. The odds ratio for
TNF inhibitors was 1.92 (95% CI 0.91, 4.03, P = 0.085). In LTE studies, the IR of TB was >40/100 000 with
tofacitinib and all biologics except rituximab. IR was higher in RA patients with anti-TNF monoclonal
antibodies [307.71 (95% CI 184.79, 454.93)] than in those with rituximab [20.0 (95% CI 0.10, 60)] and
etanercept [67.58 (95% CI 12.1, 163.94)] or AS, PsA and psoriasis with etanercept [60.01 (95% CI 3.6,
184.79)]. The IR of TB was higher in high-background TB areas.
Conclusion. RCTs are not sensitive enough to assess the risk of reactivation of latent TB infection (LTBI).
Disease, treatment and background TB rate are associated with different frequencies of active TB. The
benefit/risk balance of preventing reactivation of LTBI in different backgrounds should be considered in
clinical practice.
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Introduction
The appearance of biologic therapies was an important
advancement in the treatment of immune-mediated
chronic inflammatory diseases (IMIDs) such as RA, AS,
PsA, psoriasis (Ps), ulcerative colitis (UC) and Crohn’s dis-
ease (CD) [14]. The anti-TNF monoclonal antibodies and
the soluble TNF receptor etanercept are TNF inhibitors
that are approved for the treatment of RA. Rituximab,
tocilizumab and abatacept have also been approved for
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the treatment of RA. For the treatment of AS, only TNF
inhibitors have been authorized. For PsA, TNF inhibitors
and ustekinumab are currently used. Recently the oral
small molecule tofacitinib was granted approval for the
treatment of RA. Observational studies and clinical trials
have reported the occurrence of non-opportunistic and
opportunistic infections, including TB, in patients treated
with these medications [5, 6].
Most of the individuals infected with mycobacterial tu-
berculosis (TB) do not develop active disease. They either
recover or harbour the dormant mycobacteria as a latent
TB infection (LTBI). This diverse response to the infection
depends on the host. In LTBI, the mycobacteria are con-
fined by granuloma via recruitment of CD4 and CD8 T
cells, B cells and macrophages to the infected site. The
T cells produce IFN-g and the macrophages and T cells
produce TNF, which maintains the integrity of the granu-
loma. The currently available information indicates that
biologics and tofacitinib cause active TB by disrupting
the granuloma.
Controversies have emerged regarding the differences
in the risk of active TB during treatment of IMID with bio-
logics [7]. Most information is from observational studies
and refers to the risk of TNF inhibitors in patients included
in registries. Registries provide sound evidence in se-
lected populations in real life, but they have drawbacks:
the recruitment methods and inclusion criteria for both
biologic and comparator cohorts are different, the
non-exposed internal cohort used for comparison is
sometimes missing, the patient demographics and co-
morbidities are different and the analytic approaches are
dissimilar [8, 9]. Recommendations for the management
of LTBI in patients treated with biologics are mostly con-
cerned with TNF inhibitors.
The main objective of this review was to assess the
risk of the development of active TB in patients suffering
from IMID and treated with biologics and tofacitinib
in randomized controlled trials (RCTs) and long-term
extension (LTE) studies compared with controls. The
secondary objective was to investigate the association
of the rate of active TB with the type of medication
(biologic/tofacitinib), treated disease and location of the
study.
Materials and methods
A systematic literature review to identify all publications
that analysed the incidence of TB in IMID patients treated
with biologics and tofacitinib in RCTs and LTE studies was
performed. Data regarding indications that were not
approved were dismissed. The Preferred Reporting
Items for Systematic Reviews and Meta-Analyses
(PRISMA) consensus was followed for the review and
meta-analysis [10]. The review was divided into two
parts: (i) analysis of RCTs that contained a comparator
group (treatment and control groups with similar exposure
times) and (ii) analysis of LTE studies (only actively treated
patients).
Systematic literature search
A comprehensive search of the literature was performed
using the Medline, Embase, Cochrane Library and Web of
Knowledge electronic databases for articles published
through January 2013. The search strategy focused on
synonyms of diseases, biologics and tofacitinib and was
limited to human subjects and articles published in the
English language. Controlled vocabularies (e.g. Medical
Subject Heading terms) were used to identify synonyms
(see the example of searching in PubMed in the supple-
mentary data, available at Rheumatology Online).
Selection criteria for articles
The selection criteria were (i) studies including patients at
least 18 years of age with a diagnosis of RA, AS, PsA, Ps,
UC or CD; (ii) studies of patients treated for at least 12
weeks with infliximab, adalimumab, golimumab, certolizu-
mab, etanercept, abatacept, rituximab, tocilizumab, uste-
kinumab or tofacitinib; (iii) studies collecting data on TB;
(iv) RCTs and (v) studies with a control group.
The study selection was performed based on the inclu-
sion criteria. Two independent reviewers (A.S. and E.S.)
selected the articles in a standardized manner by reading
the titles and abstracts. A third reviewer (J.R.M.) selected
the articles if the first two reviewers were in disagreement.
Abstracts and duplicate publications were dismissed.
Additionally, articles including previously biologic-treated
patients were dismissed. Once the unrelated articles were
excluded, the full texts of the selected studies were exam-
ined. Subsequently, articles not fulfilling all selection cri-
teria were excluded. A table with the reasons for exclusion
was constructed (see supplementary Table S1, available
at Rheumatology Online). A reverse search of the included
articles and a hand search of the published clinical trials of
biologics and tofacitinib were also performed. For the
second part of the review, LTE studies were also included.
In the LTE studies, some patients had been treated pre-
viously with a biologic. The last update of the manual
search of the LTE studies was completed in June 2013.
Data extraction
The data collection included publication details, number
of patients, characteristics of the trial participants, study
design, study duration, study quality, level of evidence,
type of intervention, incidence cases of TB, year of initi-
ation of the study, geographic location of the study clas-
sified according to the rate of TB (World Health
Organization, incidence TB estimation, 2011), previous
latent TB screening and treatment, and characteristics
of the current and previous treatments. Countries with
an incidence rate (IR) 540/100 000 are considered as
high-incidence TB areas.
Risk of bias
The systematic review included RCTs and their LTE
phase. Unblinded studies were permitted. The quality of
the studies was assessed by the Jadad scale [11]. The
level of evidence of the studies was assessed by the
www.rheumatology.oxfordjournals.org 1873
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Oxford Centre for Evidence-Based Medicine (OCEBM)
Levels of Evidence [12].
Statistical analysis
Meta-analyses were only performed when at least three
studies had comparable outcome measures using a
random-effects approach with the DerSimonian and
Laird method and the odds ratio (OR) had been computed
[13]. An OR >1 suggests a higher risk of TB than the con-
trol. Studies without active TB cases were excluded for
meta-analysis of RCTs. For each available analysis, the
effect was plotted by the inverse of its standard error to
identify the risk of publication bias by visually assessing
the symmetry of the funnel plots. Its statistical significance
was checked using the Egger test [14]. A P-value <0.05
was considered indicative of publication bias. The hetero-
geneity was tested using I2 [15, 16].
The LTE studies were meta-analysed using random ef-
fects. The effect estimates were calculated as a pooled
estimated IR (per 100 000 patient-years). Explanations for
heterogeneity were investigated using sensitivity analysis,
meta-regression and stratified analysis. Meta-regression
aimed to determine the influence of the type of medica-
tion, disease under treatment, study year, TB rate of
included areas and previous biologics exposure on the
rate of active TB. A P-value <0.10 was considered signifi-
cant in the meta-regression. Stratified analyses were con-
ducted by type of medication, disease under treatment
and TB rate of the included area. Stata/IC 11.1 for
Windows (StataCorp, College Station, TX, USA) was
used for all statistical analyses.
Results
Study selection
The search identified 11 130 articles and abstracts. After
screening, 182 articles were retrieved for review. By hand
and reverse searching, 22 articles were additionally
included. After reading the full text, 99 articles, including
100 RCTs, were selected for analysis (see Fig. 1). By hand
searching, 63 LTE documents, including 1 US Food and
Drug Administration (FDA) document, were identified and
included for the second objective.
Meta-analysis of RCTs
A total of 100 RCTs with approximately 75 000 patients
were analysed. Fifty-five RCTs were on RA, 18 on Ps, 9
on AS, 8 on PsA, 5 on CD and 5 on UC. Twenty RCTs
involved treatment with infliximab, 19 with etanercept, 18
with adalimumab, 9 with tocilizumab, 7 with golimumab, 7
with certolizumab, 6 with abatacept, 5 with ustekinumab,
5 with tofacitinib and 4 with rituximab. Fifty-four RCTs
were performed in areas with a low or medium rate of
TB and 35 in areas with a high rate of TB, and for 11
RCTs this information was unknown.
Only 19 RCTs reporting active TB cases could be meta-
analysed [1735]. Thirty-two active TB cases were identi-
fied in 6599 patients exposed to a biologic or tofacitinib,
and only one case was identified in 2702 control patients
(see Tables 1 and 2). In the remaining 81 RCTs there were
no cases of TB (see supplementary Tables S2 and S3,
available at Rheumatology Online).
Fourteen active TB cases occurred out of 3158 patients
treated with infliximab, 10 of 1275 patients treated with
certolizumab, 2 of 658 patients treated with etanercept,
4 of 598 patients treated with adalimumab, 1 of 477 pa-
tients treated with golimumab and 1 of 433 patients trea-
ted with abatacept. No TB cases occurred in patients
treated with rituximab, tocilizumab or tofacitinib. Only
data on the TNF inhibitors were enough to perform a
meta-analysis. The OR for all TNF inhibitors was 1.92
(95% CI 0.91, 4.03, P = 0.085), without heterogeneity
(I2= 0.0%) (see Fig. 2). No asymmetries were found in
the funnel plot (Egger test P = 0.035).
There were 26 active TB cases out of 5253 RA patients,
2 of 55 AS patients, 1 of 57 PsA patients, 1 of 653 Ps
patients, 1 of 243 UC patients and 1 of 338 CD patients.
The OR for RA was 1.87 (95% CI 0.76, 4.60, P = 0.169),
without heterogeneity (I2 = 0.0%). No asymmetries were
found in the funnel plot (Egger test P = 0.012). The data
for AS, PsA, Ps, CD and UC could not be independently
meta-analysed, therefore they were pooled and compared
with RA. The OR for the non-RA diseases was 2.01 (95%
CI 0.54, 7.50, P = 0.297). No asymmetries were found in
the funnel plot (Egger test P = 0.056).
The OR for studies that did not include high TB rate
areas was 1.89 (95% CI 0.52, 6.90, P = 0.334), without
FIG. 1 Flow of information through the different phases of
the systematic review
LTEs: long-term extension studies.
1874 www.rheumatology.oxfordjournals.org
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heterogeneity (I2 = 0.0%). No asymmetries were found in
the funnel plot (Egger test P = 0.275). The OR for active TB
cases in RCTs that included high TB rate areas was 2.27
(95% CI 0.76, 6.78, P = 0.141), without heterogeneity
(I2 = 0.0%). No asymmetries were found in the funnel
plot (Egger test P = 0.158).
Meta-analysis of the LTE studies
A total of 119 active TB cases were detected in 80 774.45
patient-years of exposure to biologics or tofacitinib in the
LTE studies [1, 19, 20, 25, 31, 3592]. TB cases occurred
4 weeks to 5 years after the initiation of the treatment (see
supplementary Table S4, available at Rheumatology
Online).
The pooled estimated IR of active TB was calculated by
the type of medication and treated disease. The IR of
active TB was 474.2 (95% CI 350.0, 640.0), without het-
erogeneity (I2 = 0.0%), with certolizumab treatment; 347.7
(95% CI 193.4, 539.2), without heterogeneity (I2= 0.0), with
infliximab treatment; 172.1 (95% CI 57.6, 341.8), without
heterogeneity (I2 = 0.0%), with golimumab treatment;
169.0 (95% CI 90.0, 300.0), without heterogeneity
(I2= 0.0%), with tofacitinib treatment; 75.6 (95% CI 36.1,
129.5), without heterogeneity (I2= 0.0%), with tocilizumab
treatment; 65.01 (95% CI 18.22, 136.84), without hetero-
geneity (I2 = 0.0%), with etanercept treatment; 60.0 (95%
CI 18.2, 125.9), without heterogeneity (I2 = 0.0%), with
abatacept treatment and 20.0 (95% CI 0.1, 60.0), without
heterogeneity (I2 = 0.0%), with rituximab treatment. The IR
with adalimumab treatment was 184.7 (95% CI 87.0,
318.8), with heterogeneity (I2 = 41.1%) (Fig. 3). Treated
disease, study year, gender and age of patients, concomi-
tant medications, inclusion of areas with a high rate of TB
(countries where trials were conducted), treatment of LTBI
and previous biologics failure were not identified as
causes of heterogeneity by meta-regression. The sensitiv-
ity analysis showed that the heterogeneity was due pri-
marily to one study [48]. When this study was excluded
from the analysis, the heterogeneity disappeared. A sub-
analysis by study year was performed. The IR of the active
TB cases in the trials starting later than 2003 (when an
awareness of the risk of TB in these patients was first
established) was 57.6 (95% CI 15.4, 129.5) with etaner-
cept treatment and 654.7 (95% CI 140.6, 1542.0) with the
infliximab and adalimumab treatment data pooled to-
gether. The IR with ustekinumab treatment was not esti-
mated because of the heterogeneity of the pooled data.
The IR of active TB cases was 136.8 (95% CI 78.4,
211.4), with heterogeneity (I2 = 70.3%), in RA patients trea-
ted with biologics and tofacitinib and 225.4 (95% CI 125.9,
353.6), with heterogeneity (I2 = 60.5%), in RA patients trea-
ted with TNF inhibitors. Treated disease, study year,
FIG. 2 Meta-analysis of odd ratios of cases of active tuberculosis in randomized controlled trials treated with TNF
inhibitors
ETA: etanercept; IFX: infliximab; GOL: golimumab; ADA: adalimumab; CZP: certolizumab; OR: odds ratio.
www.rheumatology.oxfordjournals.org 1877
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gender and age of patients, concomitant medications, in-
clusion of areas with a high rate of TB, treatment of LTBI
and previous biologics failure were not identified as
causes of heterogeneity by meta-regression. The sensitiv-
ity analysis showed that the heterogeneity was due to the
inclusion of two studies [48, 60]. When these two studies
were excluded from the meta-analysis, the heterogeneity
disappeared. The IR was 654.6 (95% CI 193.4, 1374.2)
with infliximab treatment, 474.3 (95% CI 350.0, 640.0)
with certolizumab treatment, 254.8 (95% CI 70.2, 546.6)
with golimumab treatment, 193.48 (95% CI 55.21, 409.04)
with adalimumab treatment and 67.5 (95% CI 12.1, 163.9)
with etanercept treatment. The IR with etanercept was
lower than with anti-TNF monoclonal antibodies [67.6
(95% CI 12.1, 163.9) vs 307.7 (184.8, 454.9)].
The IR of active TB in patients with IBD treated with
biologics was 285.9 (95% CI 125.9, 510.3), without het-
erogeneity (I2 = 0.0%). The IR in patients with CD was
higher than in patients with UC [313.3 (95% CI 119.0,
99.4) vs. 220.7 (19.6, 638.6)]. The IR in patients with PsA
was 140.6 (95% CI 13.2, 396.4), without heterogeneity
(I2 = 14.4%); in patients with AS it was 115.6 (95% CI
30.6, 259.9), without heterogeneity (I2 = 0.0%); and in pa-
tients with Ps it was 60.0 (95% CI 1.2, 202.4), with het-
erogeneity (I2 = 42.7%) (see Fig. 4). Treated disease, study
year, gender and age of patients, concomitant medica-
tions, inclusion of areas with a high rate of TB, treatment
of LTBI and previous biologics failure were not identified
as causes of heterogeneity by meta-regression.
Heterogeneity was due to the inclusion of the two studies
with ustekinumab [89, 90]. When only trials with TNF in-
hibitors were analysed, the heterogeneity disappeared.
The IR in AS, PsA and Ps patients pooled together was
lower with etanercept than anti-TNF monoclonal antibo-
dies [60.01 (95% CI 3.6, 184.8) vs 122.4 (34.2, 264.9)].
The proportion of patients from each individual country
in the trials is not available. Seven of the nine cases of
active TB in patients treated with tocilizumab occurred in
medium/high TB rate areas in LTE studies [60, 86, 93]. For
the tofacitinib-treated patients, the IR of active TB per
100 000 was 781, 36 and 37 in high, medium and low
TB rate areas, respectively [94]. For certolizumab-treated
patients, the IR was 50, 230, 580, and 1020 in North
America, Western Europe, Central Europe and Eastern
Europe, respectively [95].
Discussion
Our work shows that an increased rate of reactivation of
LTBI with biologics and tofacitinib cannot be demon-
strated in RCTs. Only 19% of the RCTs had TB cases.
The meta-analysis was only performed for the TNF inhibi-
tor trials because there was only one case of TB in the
RCTs with abatacept and none with other biologics and
tofacitinib. Moreover, for the individual RCTs of patients
treated with TNF inhibitors, a rate could not be assessed
FIG. 3 Meta-analysis of incidence rates by treatment of long-term extension studies
ES: incidence rate per 100 000 patient-years; ABA: abatacept; ETA: etanercept; TOC: tocilizumab; TOF: tofacitinib; GOL:
golimumab; ADA: adalimumab; IFX: infliximab; CZP: certolizumab; UST: ustekinumab; RIT: rituximab.
1878 www.rheumatology.oxfordjournals.org
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or was not different from the controls. This is likely due to
insufficient exposure pertaining to the design of the RCTs
and the number of patients. In line with this, the first study
that indicated the reactivation of LTBI in patients with RA
was an analysis of all cases of active TB after infliximab
therapy through the MedWatch spontaneous reporting
system of the FDA [96].
In LTE studies, the IR of active TB was high (>40/
100 000) for patients with tofacitinib and all biologics but
rituximab. In addition, treated disease, the rate of TB in
the background population and treatment were asso-
ciated with a higher rate of TB. Interestingly, the rate of
TB in RA patients, but not in the patients with the other
diseases, not treated with biologics was increased com-
pared with the control population, and treatment with bio-
logics further increased this rate [5, 97101]. This would
explain the higher risk in RA patients compared with the
other IMIDs in our work. Heterogeneity was found in RA
and Ps, and a sensitivity analysis showed that it was par-
tially due to three studies. When these studies were
excluded, the heterogeneity disappeared. One study on
RA with the largest number of patients included quite dis-
similar patients [48]. The second study had a very large
exposure and reported a large number of TB cases [60]. In
Ps, the heterogeneity was primarily due to ustekinumab
studies. In one study, no cases of TB in an exposure of
4782 patient-years were reported [90]. In another study on
Taiwanese and Korean patients, one case occurred in
69.8 patient-years [89].
Extensive reviews of the risk of reactivation of latent TB
following therapy with TNF antagonists, largely from ob-
servational studies, have been published [102, 103].
Following TNF antagonist therapy, the relative risk for TB
is increased, depending on the clinical setting and the
TNF antagonist used. However, significant differences in
the rate of active TB from study to study are reported with
adalimumab, etanercept and infliximab. Data for golimu-
mab, certolizumab, abatacept, tocilizumab, rituximab and
tofacitinib are meagre.
A large number of active TB cases occurred in patients
treated with certolizumab, tocilizumab and tofacitinib in
areas with high background rates of TB [60, 86, 93, 94].
Hence, safety studies should include patients from these
areas to develop a true picture of the risk of this infection.
A higher IR of active TB with anti-TNF monoclonal anti-
bodies than with etanercept was observed. This differ-
ence was also observed in sub-analyses of RA, AS, PsA
and Ps. In observational studies, whether the IR with anti-
FIG. 4 Meta-analysis of incidence rates by disease of long-term extension studies
ES: incidence rate per 100 000 patient-years; Ps: psoriasis; CD: Crohn’s disease; UC: ulcerative colitis; RA-TNFi: RA
treated with a TNF inhibitor; RA-IFX: RA treated with infliximab; RA-ETA: RA treated with etanercept; RA-ADA: RA treated
with adalimumab; RA-GOL: RA treated with golimumab; RA-CZP: RA treated with certolizumab.
www.rheumatology.oxfordjournals.org 1879
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TNF monoclonal antibodies is greater than that with eta-
nercept is controversial [7, 104107]. The first trials report-
ing TB cases were conducted before the dissemination of
the general recommendations for the management of
LTBI. Nevertheless, in the trials starting later than 2003,
a lower rate of TB with etanercept than with infliximab or
adalimumab was also demonstrated, excluding the bias
related to the trial starting date. Interestingly, certolizumab
has the highest IR. However, this should be carefully in-
terpreted because the certolizumab trials included a much
higher percentage of patients from TB endemic areas than
the other trials. Of additional interest is the lower rate of
active TB in patients with spondyloarthritis treated with
etanercept, and possibly in Ps patients treated with uste-
kinumab and RA patients treated with rituximab, com-
pared with RA patients treated with monoclonal
antibodies. This low rate of rituximab could merely repre-
sent the background rate of TB in RA patients. The IR of
tofacitinib was similar to that for anti-TNF monoclonal
antibodies. Other biologics, such as abatacept or tocilizu-
mab, had a lower IR.
One possible explanation for the differences regarding
the reactivation of latent TB is the mechanism of action of
these medications. In vitro and in vivo, monoclonal anti-
bodies cross-link trans-membrane TNF and induce apop-
tosis of T cells, which are relevant for granuloma integrity.
Etanercept is a soluble receptor and does not have this
activity. Moreover, the complement-mediated lysis of
TNF-expressing T cells is different. Etanercept, but not
the monoclonal antibodies, lacks the CH1 domain where
C3 attaches, resulting in a different interaction of etaner-
cept with the complement system. Insufficient IFN-g pro-
duction is also important in the reactivation of latent TB.
TNF inhibitors inhibit the IFN-g production induced by TB
antigens, while abatacept, tocilizumab and rituximab do
not. Additionally, the CTLA-4 fusion protein abatacept
does not affect mycobacterial infection-induced lympho-
cyte expansion or cytokine production and does not alter
the number or function of the lymphocytes that maintain
the integrity of the granuloma [108, 109]. Inhibition of
Janus kinase 1 (JAK1) and JAK3 by tofacitinib blocks
intracellular signals by cytokines that are important for
lymphocyte function and modulate the immune response.
Animal models have demonstrated that tofacitinib re-
duces the ability of the host to contain latent TB and en-
hances the reactivation of latent infection [94, 110, 111].
Differences in TB reactivation might be related to the dif-
ferent roles of biologics and tofacitinib in the modulation
of the acquired immune response and the preservation of
granuloma integrity [112].
The inclusion of a large number of patients, the con-
cordance and the low heterogeneity of the results, and
the analysis of long time exposures to biologics in LTE
studies are among the strengths of our review. The limi-
tations of our review are the short time exposures of the
RCTs and the lack of patients from high TB rate countries
in the early studies. The short exposures to treatments in
the RCTs might have caused an underestimation of the TB
rates. Undoubtedly there are design differences in the
trials. Another weakness is how the analysis of areas
included in the trials was reported. Some studies reported
the areas where the trial was conducted but not the
number of patients from those areas. Information regard-
ing the screening of TB was not consistently reported. In
the studies with the highest rates, screening was included
in the selection of patients. However, management of
positive cases was based on local guidelines (not
described in reports). Thus the results must be carefully
interpreted. Publication bias might be considered in the
meta-analysis of TNF inhibitors in RCTs, although ORs
were not significant and funnel plots were symmetric.
Our results may have direct implications in the manage-
ment of a large number of patients treated currently with
biologics and tofacitinib. Isoniazid is the current standard
treatment for LTBI, but its liver toxicity is a major concern.
The risk factors for this complication have been estab-
lished, and the selection of candidates to avert this rare
but severely adverse event has been proposed [113115].
In selected populations, the benefit/risk balance may not
favour the implementation of recommendations to prevent
the reactivation of LTBI. Future studies should answer this
question in patients treated with biologics and tofacitinib
with a low risk of TB and a high risk of liver toxicity. On the
other hand, reinforcement of the recommendations in pa-
tients with high risk is essential for all biologics and tofa-
citinib. Of note, observational studies and clinical trials
have demonstrated the benefit of the treatment of LTBI
[95, 104]. Finally, RCTs are not sensitive enough to assess
the risk of reactivation of LTBI. This should be taken into
account before definitive statements about the risk of TB
in patients treated with biologics and the new small mol-
ecule tofacitinib are made.
Rheumatology key messages
. Different risk of tuberculosis is related to disease,
selected treatment and background tuberculosis.
. The benefit/risk balance of preventing reactivation
of latent tuberculosis infection should be con-
sidered individually.
Acknowledgements
Author contributions: A.S.: study design, literature search
and selection of papers for inclusion, data collection and
interpretation, creation of figures and tables, and drafting
the article. E.S. and J.R.M.: study design, literature search
and selection of papers for inclusion and interpretation of
data. L.C.: study design and interpretation of data. J.J.G.-
R: conception and study design, interpretation of data,
and drafting and critical revising of the article for important
intellectual contributions. All authors gave final approval of
the version of the manuscript to be published.
Disclosure statement: J.J.G.-R. is on the advisory boards
of BMS, Pfizer, Roche, Schering-Plough and UCB SA; has
received lecture fees from BMS, Roche, Schering-Plough
and Wyeth; and has received research grants from Roche
1880 www.rheumatology.oxfordjournals.org







atology/article/53/10/1872/1816712 by guest on 25 January 2021
and Schering-Plough. L.C. has received lecture fees from
Abbott and Pfizer. All other authors have declared no
conflicts of interest.
Supplementary data
Supplementary data are available at Rheumatology
Online.
References
1 Baraliakos X, Listing J, Fritz C et al. Persistent clinical ef-
ficacy and safety of infliximab in ankylosing spondylitis
after 8 years—early clinical response predicts long-term
outcome. Rheumatology 2011;50:16909.
2 Scott DL. Biologics-based therapy for the treatment of
rheumatoid arthritis. Clin Pharmacol Ther 2012;91:3043.
3 Perrier C, Rutgeerts P. Cytokine blockade in inflammatory
bowel diseases. Immunotherapy 2011;3:134152.
4 Bansback N, Sizto S, Sun H et al. Efficacy of systemic
treatments for moderate to severe plaque psoriasis: sys-
tematic review and meta-analysis. Dermatology 2009;219:
20918.
5 Askling J, Fored CM, Brandt L et al. Risk and case char-
acteristics of tuberculosis in rheumatoid arthritis asso-
ciated with tumor necrosis factor antagonists in Sweden.
Arthritis Rheum 2005;52:198692.
6 Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM,
Montero MD. Treatment of rheumatoid arthritis with tumor
necrosis factor inhibitors may predispose to significant
increase in tuberculosis risk: a multicenter active-surveil-
lance report. Arthritis Rheum 2003;48:21227.
7 Tubach F, Salmon D, Ravaud P et al. Risk of tuberculosis
is higher with anti-tumor necrosis factor monoclonal anti-
body therapy than with soluble tumor necrosis factor re-
ceptor therapy: the three-year prospective French
Research Axed on Tolerance of Biotherapies registry.
Arthritis Rheum 2009;60:188494.
8 Curtis JR, Jain A, Askling J et al. A comparison of patient
characteristics and outcomes in selected European and
U.S. rheumatoid arthritis registries. Semin Arthritis Rheum
2010;40:214, e1.
9 Zink A, Askling J, Dixon WG et al. European biologicals
registers: methodology, selected results and perspec-
tives. Ann Rheum Dis 2009;68:12406.
10 Liberati A, Altman DG, Tetzlaff J et al. The PRISMA state-
ment for reporting systematic reviews and meta-analyses
of studies that evaluate health care interventions: explan-
ation and elaboration. J Clin Epidemiol 2009;62:e134.
11 Jadad AR, Moore RA, Carroll D et al. Assessing the quality
of reports of randomized clinical trials: is blinding neces-
sary? Control Clin Trials 1996;17:112.
12 Centre for Evidence Based Medicine. Levels of Evidence
Working Group. Centre for Evidence Based Medicine,
University of Oxford, Oxford, UK.
13 DerSimonian R, Laird N. Meta-analysis in clinical trials.
Control Clin Trials 1986;7:17788.
14 Egger M, Davey Smith G, Schneider M, Minder C. Bias in
meta-analysis detected by a simple, graphical test. BMJ
1997;315:62934.
15 Higgins JP, Thompson SG. Quantifying heterogeneity in a
meta-analysis. Stat Med 2002;21:153958.
16 Higgins JP, Thompson SG, Deeks JJ, Altman DG.
Measuring inconsistency in meta-analyses. BMJ 2003;
327:55760.
17 Combe B, Codreanu C, Fiocco U et al. Etanercept and
sulfasalazine, alone and combined, in patients with active
rheumatoid arthritis despite receiving sulfasalazine: a
double-blind comparison. Ann Rheum Dis 2006;65:
135762.
18 Maini R, St Clair EW, Breedveld F et al. Infliximab (chimeric
anti-tumour necrosis factor alpha monoclonal antibody)
versus placebo in rheumatoid arthritis patients receiving
concomitant methotrexate: a randomised phase III trial.
ATTRACT Study Group. Lancet 1999;354:19329.
19 Barker J, Hoffmann M, Wozel G et al. Efficacy and safety
of infliximab vs. methotrexate in patients with moderate-
to-severe plaque psoriasis: results of an open-label,
active-controlled, randomized trial (RESTORE1). Br J
Dermatol 2011;110917.
20 Emery P, Fleischmann RM, Moreland LW et al.
Golimumab, a human anti-tumor necrosis factor alpha
monoclonal antibody, injected subcutaneously every four
weeks in methotrexate-naive patients with active
rheumatoid arthritis: twenty-four-week results of a phase
III, multicenter, randomized, double-blind, placebo-
controlled study of golimumab before methotrexate as
first-line therapy for early-onset rheumatoid arthritis.
Arthritis Rheum 2009;60:227283.
21 Chen D-Y, Chou S-J, Hsieh T-Y et al. Randomized,
double-blind, placebo-controlled, comparative study of
human anti-TNF antibody adalimumab in combination with
methotrexate and methotrexate alone in Taiwanese pa-
tients with active rheumatoid arthritis. J Formos Med
Assoc 2009;108:3109.
22 Keystone EC, Kavanaugh AF, Sharp JT et al.
Radiographic, clinical, and functional outcomes of treat-
ment with adalimumab (a human anti-tumor necrosis
factor monoclonal antibody) in patients with active
rheumatoid arthritis receiving concomitant methotrexate
therapy: a randomized, placebo-controlled, 52-week trial.
Arthritis Rheum 2004;140011.
23 Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for
induction and maintenance therapy for ulcerative colitis. N
Engl J Med 2005;353:246276.
24 van der Heijde D, Klareskog L, Rodriguez-Valverde V et al.
Comparison of etanercept and methotrexate, alone and
combined, in the treatment of rheumatoid arthritis: two-
year clinical and radiographic results from the TEMPO
study, a double-blind, randomized trial. Arthritis Rheum
2006;54:106374.
25 Colombel JF, Sandborn WJ, Reinisch W et al. Infliximab,
azathioprine, or combination therapy for Crohn’s disease.
N Engl J Med 2010;362:138395.
26 Keystone E, Heijde D, Mason D Jr et al. Certolizumab
pegol plus methotrexate is significantly more effective
than placebo plus methotrexate in active rheumatoid
arthritis: findings of a fifty-two-week, phase III,
multicenter, randomized, double-blind, placebo-
controlled, parallel-group study. Arthritis Rheum 2008;58:
331929.
www.rheumatology.oxfordjournals.org 1881







atology/article/53/10/1872/1816712 by guest on 25 January 2021
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